<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-170-13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GEMCITABINE ACTAVIS 1 GM
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GEMCITABINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        289.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACTAVIS SPA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACTAVIS SPA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 461]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            QOMEL MEDICAL DRUG STORE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ACTAVIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gemcitabine powder for solution for infusion belongs to a group of medicines called &ldquo;cytotoxics&rdquo;. These medicines kill dividing cells, including cancer cells. Gemcitabine powder for solution for infusion may be given alone or in combination with other anti-cancer medicines, depending on the type of cancer. Gemcitabine powder for solution for infusion is used in the treatment of the following types of cancer: &middot; non-small cell lung cancer (NSCLC), alone or together with cisplatin &middot; pancreatic cancer. &middot; breast cancer, together with paclitaxel. &middot; ovarian cancer, together with carboplatin. &middot; bladder cancer, together with cisplatinGemcitabine powder for solution for infusion belongs to a group of medicines called &ldquo;cytotoxics&rdquo;. These medicines kill dividing cells, including cancer cells. Gemcitabine powder for solution for infusion may be given alone or in combination with other anti-cancer medicines, depending on the type of cancer. Gemcitabine powder for solution for infusion is used in the treatment of the following types of cancer: &middot; non-small cell lung cancer (NSCLC), alone or together with cisplatin &middot; pancreatic cancer. &middot; breast cancer, together with paclitaxel. &middot; ovarian cancer, together with carboplatin. &middot; bladder cancer, together with cisplatin</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You should not be given Gemcitabine powder for solution for infusion: - if you are allergic (hypersensitive) to gemcitabine or any of the other ingredients of Gemcitabine powder for solution for infusion (listed in section 6). - if you are breast-feeding Take special care with Gemcitabine powder for solution for infusion: Before the first infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function. Before each infusion you will have samples of your blood taken to evaluate if you have enough blood cells to receive Gemcitabine powder for solution for infusion. Your doctor may decide to change the dose or delay treating you depending on your general condition and if your blood cell counts are too low. Periodically you will have samples of your blood taken to evaluate your kidney and liver function. Please tell your doctor if: &middot; you have, or have previously had liver disease, heart disease or vascular disease. &middot; you have recently had, or are going to have radiotherapy, &middot; you have been vaccinated recently &middot; you develop breathing difficulties or feel very weak and are very pale (may be a sign of kidney failure). &middot; you develop generalised swelling, shortness of breathor weight gain, as this may be a sign of fluid leaking from your small blood vessels into the tissue, and symptoms of a serious condition called Capillary Leak Syndrome (CLS). &middot; you during treatment with this medicine get symptoms such as headache with confusion, seizures (fits) or changes in vision. You should contact your doctor right away, as this could be a very rare nervous system side effect named posterior reversible encephalopathy syndrome (PRES). Taking other medicines Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including vaccinations and medicines obtained without a prescription. Pregnancy and breast-feeding If you are pregnant, or thinking about becoming pregnant, tell your doctor. The use of Gemcitabine powder for solution for infusion should be avoided during pregnancy. Your doctor will discuss with you the potential risk of taking Gemcitabine powder for solution for infusion during pregnancy. Fertility Men are advised not to father a child during and up to 6 months following treatment with Gemcitabine powder for solution for infusion. If you would like to father a child during the treatment or in the 6 months following treatment, seek advice from your doctor or pharmacist. You may want to seek counselling on sperm storage before starting your therapy. If you are breast-feeding, tell your doctor. You must discontinue breast-feeding during Gemcitabine powder for solution for infusion treatment. Driving and using machines Gemcitabine powder for solution for infusion may make you feel sleepy, particularly if you have consumed any alcohol. Do not drive a car or use machinery until you are sure that Gemcitabine powder for solution for infusion treatment has not made you feel sleepy. Important information about some of the ingredients of Gemcitabine powder for solution for infusion Gemcitabine powder for solution for infusion contains 3.5 mg (&lt; 1 mmol) of sodium in each 200 mg vial, 17.5 mg (&lt; 1 mmol) sodium in each 1000 mg vial and 35 mg (1.52 mmol) sodium in each 2000 mg vial. This should be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The usual dose of Gemcitabine is 1000-1250 mg for every square meter of your body&rsquo;s surface area. Your height and weight are measured to work out the surface area of your body. Your doctor will use this body surface area to work out the right dose for you. This dosage may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition. How frequently you receive your Gemcitabine powder for solution for infusion depends on the type of cancer that you are being treated for. A hospital pharmacist or doctor will have dissolved the Gemcitabine powder before it is given to you. You will always receive Gemcitabine by infusion into one of your veins. The infusion will last approximately 30 minutes. If you have further questions on the use of this product ask your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Gemcitabine powder for solution for infusion can cause side effects, although not everybody gets them. Frequencies of the observed side effects are defined as: &middot; very common: affects more than 1 user in 10 &middot; common: affects 1 to 10 users in 100 &middot; uncommon: affects 1 to 10 users in 1,000 &middot; rare: affects 1 to 10 users in 10,000 &middot; very rare: affects less than 1 user in 10,000 &middot; not known: frequency can&rsquo;t be estimated from the available data You must contact your doctor immediately if you notice any of the following: &middot; Fever or infection (common): if you have a temperature of 38&ordm;C or greater, sweating or other signs of infection (since you might have less white blood cells than normal which is very common). &middot; Irregular heart rate (arrhythmia) (frequency not known). &middot; Pain, redness, swelling or sores in your mouth (common). &middot; Allergic reactions: if you develop skin rash (very common) / itching (common), or fever (very common). &middot; Tiredness, feeling faint, becoming easily breathless or if you look pale (since you might have less haemoglobin than normal which is very common). &middot; Bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising (since you might have less platelets than normal which is very common). &middot; Difficulty breathing (it is very common to have mild breathing difficulty soon after the Gemcitabine infusion which soon passes, however uncommonly or rarely there can be more severe lung problems) &middot; Generalised swelling, shortness of breath or weight gain, as you might have fluid leakage from small blood vessels into tissues (capillary leak syndrome) (very rare). &middot; Headache with changes in vision, confusion, seizures or fits (posterior reversible encephalopathy syndrome) (very rare). &middot; Extreme tiredness and weakness, purpura or small areas of bleeding in the skin (bruises), acute renal failure (low urine output or no urine output), and signs of infection. These may be features of thrombotic microangiopathy (clots forming in small blood vessels) and haemolytic uraemic syndrome, which may be fatal. Side effects with Gemcitabine powder for solution for infusion may include: Very common side effects Low haemoglobin level (anaemia) Low white blood cells Low platelet count Difficulty breathing Vomiting Nausea Skin rash- allergic skin rash, frequently itchy Hair loss Liver problems: found through abnormal blood test results Blood in urine Abnormal urine tests: protein in urine Flu like symptoms including fever Oedema (swelling of ankles, fingers, feet, face) Common side effects Fever accompanied by low white blood cell count (febrile neutropenia) Anorexia (poor appetite) Headache Insomnia Sleepiness Cough Runny nose Constipation Diarrhoea Pain, redness, swelling or sores in the mouth Itching Sweating Muscle pain Back pain Fever Weakness Chills Infections Uncommon side effects Interstitial pneumonitis (scarring of the air sacs of the lung) Spasm of the airways (wheeze) Abnormal chest X ray/scan (scarring of the lungs) Rare side effects Heart attack (myocardial infarction) Low blood pressure Skin scaling, ulceration or blister formation Injection site reactions Very rare side effects Increased platelet count Anaphylactic reaction (severe hypersensitivity/ allergic reaction) Sloughing of skin and severe skin blistering Thrombotic microangiopathy: clots forming in small blood vessels Side effects with frequency not known Irregular heart beat (arrhythmia) Adult Respiratory Distress Syndrome (severe lung inflammation causing respiratory failure) Radiation recall-(a skin rash like severe sunburn) which can occur on skin that has previously been exposed to radiotherapy. Fluid in the lungs Radiation toxicity- scarring of the air sacs of the lung associated with radiation therapy Ischaemic colitis (inflammation of the lining of the large bowel, caused by reduced blood supply) Heart failure Kidney failure Gangrene of fingers or toes Serious liver damage, including liver failure Stroke Sepsis: when bacteria and their toxins circulate in the blood and starts to damage the organs Pseudocellulitis: Skin redness with swelling You might have any of these symptoms and/or conditions. You must tell your doctor as soon as possible when you start experiencing any of these side effects.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children. Do not use Gemcitabine powder for solution for infusion after the expiry date, which is stated on the carton and vial. The expiry date refers to the last day of that month. Unopened vial: This medicinal product does not require any special storage conditions. Reconstituted solution: The product should be used immediately. When prepared as directed, chemical and physical in-use stability of reconstituted solutions of gemcitabine were demonstrated for 21 days at 25&deg;C. Further dilution by a healthcare provider may be done. Solutions of reconstituted gemcitabine should not be refrigerated, as crystallisation may occur. This medicine is for single use only; any unused solution should be discarded under the local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is gemcitabine. Each vial contains 200, 1000 mg or 2000 mg of gemcitabine (as gemcitabine hydrochloride). The other ingredients are mannitol (E421), sodium acetate, hydrochloric acid and sodium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Gemcitabine powder for solution for infusion is a white to off-white powder, for solution for infusion in a vial. Each
vial contains 200 mg, 1000 mg or 2000 mg of gemcitabine. Each pack of Gemcitabine powder for solution for
infusion contains 1 vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Actavis Group PTC ehf.<br />Reykjavikurvegur 76-78<br />220 Hafnarfjordur<br />Iceland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2011
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            NA
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gemcitabine Actavis 38 mg/ml powder for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml of the reconstituted solution for infusion (see section 6.6) contains 38 mg gemcitabine (as
hydrochloride).
200 mg vial:
Each vial contains 200 mg of gemcitabine (as hydrochloride).
Contains approximately 0.15 mmol (3.56 mg) sodium per 200 mg vial.
1 g vial:
Each vial contains 1 g of gemcitabine (as hydrochloride).
Contains approximately 0.77 mmol (17.81 mg) sodium per 1 g vial.
2 g vial:
Each vial contains 2 g of gemcitabine (as hydrochloride)
Contains approximately 1.54 mmol (35.62 mg) sodium per 2 g vial.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion.
White or almost white compact aggregate. After reconstitution in sodium chloride 0.9% the solution
is clear to pale opalescent and colourless to pale yellow.
The pH of the reconstituted solution in sodium chloride 0.9% solution is 3.0 ± 0.3.
The osmolarity of the reconstituted solution (38 mg/ml of gemcitabine (as hydrochloride) in sodium
chloride 0.9% solution) is 775 mOsm/l.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1 Therapeutic indications<br />Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in<br />combination with cisplatin.<br />Gemcitabine is indicated for treatment of patients with locally advanced or metastatic<br />adenocarcinoma of the pancreas.<br />Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with<br />locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be<br />considered in elderly patients or those with performance status 2.<br />Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial<br />ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a<br />recurrence-free interval of at least 6 months after platinum-based, first-line therapy.</p><p>Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with<br />unresectable, locally recurrent or metastatic breast cancer who have relapsed following<br />adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline<br />unless clinically contraindicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gemcitabine should only be prescribed by a physician qualified in the use of anti-cancer<br />chemotherapy.<br />Recommended posology<br />Bladder cancer<br />Combination use<br />The recommended dose for gemcitabine is 1000 mg/m2, given by 30-minute infusion. The dose<br />should be given on Days 1, 8 and 15 of each 28-day cycle in combination with cisplatin. Cisplatin is<br />given at a recommended dose of 70 mg/m2 on Day 1 following gemcitabine or day 2 of each 28-day<br />cycle. This 4-week cycle is then repeated. Dosage reduction with each cycle or within a cycle may be<br />applied based upon the grade of toxicity experienced by the patient.<br />Pancreatic cancer<br />The recommended dose of gemcitabine is 1000 mg/m2, given by 30-minute intravenous infusion. This<br />should be repeated once weekly for up to 7 weeks followed by a week of rest. Subsequent cycles<br />should consist of injections once weekly for 3 consecutive weeks out of every 4 weeks. Dosage<br />reduction with each cycle or within a cycle may be applied based upon the grade of toxicity<br />experienced by the patient.<br />Non small cell lung cancer<br />Monotherapy<br />The recommended dose of gemcitabine is 1000 mg/m2, given by 30-minute intravenous infusion. This<br />should be repeated once weekly for 3 weeks, followed by a 1-week rest period. This 4-week cycle is<br />then repeated. Dosage reduction with each cycle or within a cycle may be applied based upon the<br />grade of toxicity experienced by the patient.<br />Combination use<br />The recommended dose for gemcitabine is 1250 mg/m2 body surface area given as a 30-minute<br />intravenous infusion on Day 1 and 8 of the treatment cycle (21 days). Dosage reduction with each<br />cycle or within a cycle may be applied based upon the grade of toxicity experienced by the patient.<br />Cisplatin has been used at doses between 75-100 mg/m2 once every 3 weeks.<br />Breast cancer<br />Combination use<br />Gemcitabine in combination with paclitaxel is recommended using paclitaxel (175 mg/m2)<br />administered on Day 1 over approximately 3-hours as an intravenous infusion, followed by<br />gemcitabine (1250 mg/m2) as a 30-minute intravenous infusion on Days 1 and 8 of each 21-day cycle.<br />Dose reduction with each cycle or within a cycle may be applied based upon the grade of toxicity<br />experienced by the patient. Patients should have an absolute granulocyte count of at least 1,500 (x<br />106/l) prior to initiation of gemcitabine + paclitaxel combination.</p><p>Ovarian cancer<br />Combination use<br />Gemcitabine in combination with carboplatin is recommended using gemcitabine 1000 mg/m2<br />administered on Days 1 and 8 of each 21-day cycle as a 30-minute intravenous infusion. After<br />gemcitabine, carboplatin will be given on Day 1 consistent with a target Area under curve (AUC) of<br />4.0 mg/ml&middot;min. Dosage reduction with each cycle or within a cycle may be applied based upon the<br />grade of toxicity experienced by the patient.</p><p>Monitoring for toxicity and dose modification due to toxicity<br />Dose modification due to non haematological toxicity<br />Periodic physical examination and checks of renal and hepatic function should be made to detect<br />non-haematological toxicity. Dosage reduction with each cycle or within a cycle may be applied<br />based upon the grade of toxicity experienced by the patient. In general, for severe (Grade 3 or 4)<br />non-haematological toxicity, except nausea/vomiting, therapy with gemcitabine should be withheld<br />or decreased depending on the judgement of the treating physician. Doses should be withheld until<br />toxicity has resolved in the opinion of the physician.<br />For cisplatin, carboplatin, and paclitaxel dosage adjustment in combination therapy, please refer to<br />the corresponding Summary of Product Characteristics.<br />Dose modification due to haematological toxicity<br />Initiation of a cycle<br />For all indications, the patient must be monitored before each dose for platelet and granulocyte<br />counts. Patients should have an absolute granulocyte count of at least 1,500 (x 106/l) and platelet<br />account of 100,000 (x 106/l) prior to the initiation of a cycle.<br />Within a cycle<br />Dose modifications of gemcitabine within a cycle should be performed according to the following<br />tables:<br />Dose modification</p><p><img src="data:image/png;base64,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" alt="" width="567" height="384" vspace="0" hspace="0" border="0" style="width:567px;height:384px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/png;base64,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" alt="" width="554" height="99" vspace="0" hspace="0" border="0" style="width:554px;height:99px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Dose modifications due to haematological toxicity in subsequent cycles, for all indications<br />The gemcitabine dose should be reduced to 75% of the original cycle initiation dose, in the case of<br />the following haematological toxicities:<br />&bull; Absolute granulocyte count &lt; 500 x 106/l for more than 5 days<br />&bull; Absolute granulocyte count &lt; 100 x 106/l for more than 3 days<br />&bull; Febrile neutropaenia<br />&bull; Platelets &lt; 25,000 x 106/l<br />&bull; Cycle delay of more than 1 week due to toxicity<br />Method of administration<br />The medicinal product is tolerated well during infusion and may be administered ambulant. If<br />extravasation occurs, generally the infusion must be stopped immediately and started again in<br />another blood vessel. The patient should be monitored carefully after the administration.<br />For instructions on reconstitution, see section 6.6<br />Special populations<br />Patients with renal or hepatic impairment<br />Gemcitabine should be used with caution in patients with hepatic or renal insufficiency as there is<br />insufficient information from clinical studies to allow for clear dose recommendations for these<br />patient populations (see sections 4.4 and 5.2).<br />Elderly population(&gt; 65 years)<br />Gemcitabine has been well tolerated in patients over the age of 65. There is no evidence to suggest<br />that dose adjustments, other than those already recommended for all patients, are necessary in the<br />elderly (see section 5.2).<br />Paediatric population (&lt; 18 years)<br />Gemcitabine is not recommended for use in children under 18 years of age due to insufficient data<br />on safety and efficacy.<br /><br />&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients.
Breast-feeding (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.4 Special warnings and precautions for use</p><p>Prolongation of the infusion time and increased dosing frequency have been shown to increase<br />toxicity.<br />Haematological toxicity<br />Gemcitabine can suppress bone marrow function as manifested by leucopaenia, thrombocytopaenia<br />and anaemia.<br />Patients receiving gemcitabine should be monitored prior to each dose for platelet, leucocyte and<br />granulocyte counts. Suspension or modification of therapy should be considered when drug-induced</p><p>bone marrow depression is detected (see section 4.2). However, myelosuppression is short lived and<br />usually does not result in dose reduction and rarely in discontinuation.<br />Peripheral blood counts may continue to deteriorate after gemcitabine administration has been<br />stopped. In patients with impaired bone marrow function, the treatment should be started with<br />caution. As with other cytotoxic treatments, the risk of cumulative bone-marrow suppression must<br />be considered when gemcitabine treatment is given together with other chemotherapy.<br />Hepatic insufficiency<br />Administration of gemcitabine in patients with concurrent liver metastases or a pre-existing medical<br />history of hepatitis, alcoholism or liver cirrhosis may lead to exacerbation of the underlying hepatic<br />insufficiency.<br />Laboratory evaluation of renal and hepatic function (including virological tests) should be performed<br />periodically.<br />Gemcitabine should be used with caution in patients with hepatic insufficiency or with impaired<br />renal function as there is insufficient information from clinical studies to allow clear dose<br />recommendation for this patient population (see section 4.2).<br />Concomitant radiotherapy<br />Concomitant radiotherapy (given together or &le;7 days apart): Toxicity has been reported (see section<br />4.5 for details and recommendations for use).<br />Live vaccinations<br />Yellow fever vaccine and other live attenuated vaccines are not recommended in patients treated<br />with gemcitabine (see section 4.5).<br />Cardiovascular<br />Due to the risk of cardiac and/or vascular disorders with gemcitabine, particular caution must be<br />exercised with patients presenting a history of cardiovascular events.<br />Pulmonary<br />Pulmonary effects, sometimes severe (such as pulmonary oedema, interstitial pneumonitis or adult<br />respiratory distress syndrome (ARDS)) have been reported in association with gemcitabine therapy.<br />The aetiology of these effects is unknown. If such effects develop, consideration should be made to<br />discontinuing gemcitabine therapy. Early use of supportive care measure may help ameliorate the<br />condition.</p><p>Renal<br />Clinical findings consistent with the haemolytic uraemic syndrome (HUS) were rarely reported in<br />patients receiving gemcitabine (see section 4.8). Gemcitabine should be discontinued at the first<br />signs of any evidence of microangiopathic haemolytic anaemia, such as rapidly falling haemoglobin<br />with concomitant thrombocytopaenia, elevation of serum bilirubin, serum creatinine, blood urea<br />nitrogen, or LDH. Renal failure may not be reversible with discontinuation of therapy and dialysis<br />may be required.<br />Fertility<br />In fertility studies gemcitabine caused hypospermatogenesis in male mice (see section 5.3).<br />Therefore, men being treated with gemcitabine are advised not to father a child during and up to 6<br />months after treatment and to seek further advice regarding cryoconservation of sperm prior to<br />treatment because of the possibility of infertility due to therapy with gemcitabine (see section 4.6).<br />Sodium<br />Vial of 200 mg gemcitabine contains 3.56 mg (&lt;1 mmol) sodium.<br />Vial of 1 g gemcitabine contains 17.81 mg (&lt; 1 mmol) sodium.<br />Vial of 2 g gemcitabine contains 35.62 mg (1.54 mmol) sodium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.5 Interaction with other medicinal products and other forms of interaction<br />No specific interaction studies have been performed (see section 5.2)<br />Radiotherapy<br />Concurrent (given together or &le; 7 days apart) - Toxicity associated with this multimodality therapy is<br />dependent on many different factors, including dose of gemcitabine, frequency of gemcitabine<br />administration, dose of radiation, radiotherapy planning technique, the target tissue, and target<br />volume. Pre-clinical and clinical studies have shown that gemcitabine has radiosensitising activity.<br />In a single trial, where gemcitabine at a dose of 1,000 mg/m2 was administered concurrently for up<br />to 6 consecutive weeks with therapeutic thoracic radiation to patients with non-small cell lung<br />cancer, significant toxicity in the form of severe, and potentially life threatening mucositis,<br />especially oesophagitis, and pneumonitis was observed, particularly in patients receiving large<br />volumes of radiotherapy [median treatment volumes 4,795 cm3]. Studies done subsequently have<br />suggested that it is feasible to administer gemcitabine at lower doses with concurrent radiotherapy<br />with predictable toxicity, such as a phase II study in non-small cell lung cancer, where thoracic<br />radiation doses of 66 Gy were applied concomitantly with an administration with gemcitabine<br />(600 mg/m2, four times) and cisplatin (80 mg/m2 twice) during 6 weeks. The optimum regimen for<br />safe administration of gemcitabine with therapeutic doses of radiation has not yet been determined<br />in all tumour types.<br />Non-concurrent (given &gt;7 days apart)- Analysis of the data does not indicate any enhanced toxicity<br />when gemcitabine is administered more than 7 days before or after radiation, other than radiation<br />recall. Data suggest that gemcitabine can be started after the acute effects of radiation have<br />resolved or at least one week after radiation.<br />Radiation injury has been reported on targeted tissues (e.g. oesophagitis, colitis, and pneumonitis) in<br />association with both concurrent and non-concurrent use of gemcitabine.<br />Others<br />Yellow fever and other live attenuated vaccines are not recommended due to the risk of systemic,<br />possibly fatal, disease, particularly in immunosuppressed patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no adequate data from the use of gemcitabine in pregnant women. Studies in animals have<br />shown reproductive toxicity (see section 5.3). Based on results from animal studies and the<br />mechanism of action of gemcitabine, this substance should not be used during pregnancy unless<br />clearly necessary. Women should be advised not to become pregnant during treatment with<br />gemcitabine and to warn their attending physician immediately, should this occur after all.<br />Breast-feeding<br />It is not known whether gemcitabine is excreted in human milk and adverse effects on the suckling<br />child cannot be excluded. Breast-feeding must be discontinued during gemcitabine therapy.<br />Fertility<br />In fertility studies gemcitabine caused hypospermatogenesis in male mice (see section 5.3).<br />Therefore, men being treated with gemcitabine are advised not to father a child during and up to 6<br />months after treatment and to seek further advice regarding cryoconservation of sperm prior to<br />treatment because of the possibility of infertility due to therapy with gemcitabine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However,<br />gemcitabine has been reported to cause mild to moderate somnolence, especially in combination<br />with alcohol consumption. Patients should be cautioned against driving or operating machinery until<br />it is established that they do not become somnolent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions associated with gemcitabine treatment include:<br />nausea with or without vomiting, raised liver transaminases (AST/ALT) and alkaline phosphatase,<br />reported in approximately 60% of patients; proteinuria and haematuria reported in approximately<br />50% patients; dyspnoea reported in 10-40% of patients (highest incidence in lung cancer patients);<br />allergic skin rashes occur in approximately 25% of patients and are associated with itching in 10% of<br />patients.<br />The frequency and severity of the adverse reactions are affected by the dose, infusion rate and<br />intervals between doses (see section 4.4). Dose-limiting adverse reactions are reductions in<br />thrombocyte, leucocyte and granulocyte counts (see section 4.2).<br />Clinical trial data<br />Frequencies are defined as: Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1000<br />to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1000), Very Rare (&lt;1/10,000).<br />The following table of undesirable effects and frequencies is based on data from clinical trials.<br />Within each frequency grouping, undesirable effects are presented in order of decreasing<br />seriousness.</p><p>System Organ Class Frequency grouping<br />Blood and lymphatic<br />system disorders<br />Very common<br />&bull; Leucopaenia (Neutropaenia Grade 3 = 19.3 %; Grade 4 = 6 %).<br />Bone-marrow suppression is usually mild to moderate and mostly affects the<br />granulocyte count (see section 4.2)<br />&bull; Thrombocytopaenia<br />&bull; Anaemia<br />Common<br />&bull; Febrile neutropaenia<br />Very rare<br />&bull; Thrombocytosis<br />Immune system disorders Very Rare<br />&bull; Anaphylactoid reaction<br />Metabolism and nutrition<br />disorders<br />Common<br />&bull; Anorexia<br />Nervous system disorders Common<br />&bull; Headache<br />&bull; Insomnia<br />&bull; Somnolence<br />&bull;<br />Cardiac disorders Rare<br />&bull; Myocardial infarct<br />Vascular disorders Rare<br />&bull; Hypotension</p><p>Respiratory, thoracic<br />and mediastinal<br />disorders<br />Very common<br />&bull; Dyspnoea &ndash;usually mild and passes rapidly without treatment<br />Common<br />&bull; Cough<br />&bull; Rhinitis<br />Uncommon<br />&bull; Interstitial pneumonitis (see section 4.4)<br />&bull; Bronchospasm &ndash;usually mild and transient but may require<br />parenteral treatment<br />Gastrointestinal<br />disorders<br />Very common<br />&bull; Vomiting<br />&bull; Nausea<br />Common<br />&bull; Diarrhoea<br />&bull; Stomatitis and ulceration of the mouth<br />&bull; Constipation<br />Hepatobiliary disorders Very common<br />&bull; Elevation of liver transaminases (AST and ALT) and alkaline<br />phosphatase<br />Common<br />&bull; Increased bilirubin<br />Rare<br />&bull; Increased gamma-glutamyl transferase (GGT)<br />Skin and subcutaneous<br />tissue disorders<br />Very common<br />&bull; Allergic skin rash frequently associated with pruritus<br />&bull; Alopecia<br />Common<br />&bull; Itching<br />&bull; Sweating<br />Rare<br />&bull; Ulceration<br />&bull; Vesicle and sore formation<br />&bull; Scaling<br />Very rare<br />&bull; Severe skin reactions, including desquamation and bullous skin<br />eruptions<br />Musculoskeletal and<br />connective tissue<br />disorders<br />Common<br />&bull; Back pain<br />&bull; Myalgia<br />Renal and urinary<br />disorders<br />Very Common<br />&bull; Haematuria<br />&bull; Mild proteinuria</p><p>General disorders and<br />administration site<br />conditions<br />Very common<br />&bull; Influenza-like symptoms - the most common symptoms are fever,<br />headache, chills, myalgia, asthenia and anorexia. Cough, rhinitis,<br />malaise, perspiration and sleeping difficulties have also been<br />reported.<br />&bull; Oedema/peripheral oedema-including facial oedema. Oedema is<br />usually reversible after stopping treatment<br />Common<br />&bull; Fever<br />&bull; Asthenia<br />&bull; Chills<br />Rare<br />&bull; Injection site reactions-mainly mild in nature<br />Injury, poisoning, and<br />procedural Complications<br />Radiation toxicity (see section 4.5).</p><p>Postmarketing experience (spontaneous reports) frequency not known (can&rsquo;t be estimated from<br />the available data)<br />Nervous system disorders<br />Cerebrovascular accident<br />Cardiac disorders<br />Arrythmias, predominantly supraventricular in nature<br />Heart failure<br />Vascular disorders<br />Clinical signs of peripheral vasculitis and gangrene<br />Respiratory, thoracic and mediastinal disorders<br />Pulmonary oedema<br />Adult respiratory distress syndrome (see section 4.4)<br />Gastrointestinal disorders<br />Ischaemic colitis<br />Hepatobiliary disorders<br />Serious hepatotoxicity, including liver failure and death<br />Skin and subcutaneous tissue disorders<br />Severe skin reactions, including desquamation and bullous skin eruptions, Lyell&rsquo;s Syndrome, Steven-<br />Johnson Syndrome<br />Renal and urinary disorders<br />Renal failure (see section 4.4)<br />Haemolytic uraemic syndrome (see section 4.4)<br />Injury, poisoning and procedural complications<br />Radiation recall</p><p>Combination use in breast cancer<br />The frequency of grade 3 and 4 haematological toxicities, particularly neutropaenia, increases when<br />gemcitabine is used in combination with paclitaxel. However, the increase in these adverse reactions<br />is not associated with an increased incidence of infections or haemorrhagic events. Fatigue and<br />febrile neutropaenia occur more frequently when gemcitabine is used in combination with<br />paclitaxel. Fatigue, which is not associated with anaemia, usually resolves after the first cycle.<br />Grade 3 and 4 Adverse Events<br />Paclitaxel versus gemcitabine plus paclitaxel<br />Number (%) of Patients<br />Paclitaxel arm<br />(N=259)<br />Gemcitabine plus Paclitaxel<br />arm (N=262)<br />Grade 3 Grade 4 Grade 3 Grade 4<br />Laboratory<br />Anaemia 5 (1.9) 1 (0.4) 15 (5.7) 3 (1.1)<br />Thrombocytopaenia 0 0 14 (5.3) 1 (0.4)<br />Neutropaenia 11 (4.2) 17 (6.6)* 82 (31.3) 45 (17.2)*<br />Non-laboratory<br />Febrile<br />neutropaenia<br />3 (1.2) 0 12 (4.6) 1(0.4)<br />Fatigue 3 (1.2) 1 (0.4) 15 (5.7) 2 (0.8)<br />Diarrhoea 5 (1.9) 0 8 (3.1) 0<br />Motor neuropathy 2(0.8) 0 6(2.3) 1(0.4)<br />Sensory neuropathy 9(3.5) 0 14(5.3) 1(0.4)<br />*Grade 4 neutropaenia lasting for more than 7 days occurred in 12.6% of patients in the<br />combination arm and 5.0% of patients in the paclitaxel arm.<br />Combination use in bladder cancer</p><p>Grade 3 and 4 Adverse Events<br />MVAC versus Gemcitabine plus cisplatin<br />Number (%) of Patients<br />MVAC (methotrexate, vinblastine,<br />doxorubicin and cisplatin) arm<br />(N=196)<br />Gemcitabine plus cisplatin arm<br />(N=200)<br />Grade 3 Grade 4 Grade 3 Grade 4<br />Laboratory<br />Anaemia 30(16) 4(2) 47(24) 7(4)<br />Thrombocytopaenia 15(8) 25(13) 57(29) 57(29)<br />Non-laboratory<br />Nausea and vomiting 37(19) 3(2) 44(22) 0(0)<br />Diarrhoea 15(8) 1(1) 6(3) 0(0)<br />Infection 19(10) 10(5) 4(2) 1(1)<br />Stomatitis 34(18) 8(4) 2(1) 0(0)</p><p>Combination use in ovarian cancer<br />Grade 3 and 4 Adverse Events<br />Carboplatin versus Gemcitabine plus carboplatin<br />Number (%) of Patients<br />Carboplatin arm<br />(N=174)<br />Gemcitabine plus carboplatin<br />arm<br />(N=175)<br />Grade 3 Grade 4 Grade 3 Grade 4<br />Laboratory<br />Anaemia 10(5.7) 4(2.3) 39(22.3) 9(5.1)<br />Neutropaenia 19(10.9) 2(1.1) 73(41.7) 50(28.6)<br />Thrombocytopaenia 18(10.3) 2(1.1) 53(30.3) 8(4.6)<br />Leucopaenia 11(6.3) 1(0.6) 84(48.0) 9(5.1)<br />Non-laboratory<br />Haemorrhage 0(0.0) 0(0.0) 3(1.8) (0.0)<br />Febrile neutropaenia 0(0.0) 0(0.0) 2(1.1) (0.0)<br />Infection without<br />Neutropaenia<br />0(0) 0(0.0) (0.0) 1(0.6)<br />Sensory neuropathy was also more frequent in the combination arm than with single agent<br />carboplatin&rdquo;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known antidote for overdose of gemcitabine. Doses as high as 5700 mg/m2 have been<br />administered by intravenous infusion over 30 minutes every 2 weeks with clinically acceptable<br />toxicity. In the event of suspected overdose, the patient should be monitored with appropriate blood<br />counts and receive supportive therapy, as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 Pharmacodynamic properties<br />Pharmacotherapeutic group: pyrimidine analogues ATC code: L01BC05<br />Cytotoxic activity in cell cultures<br />Gemcitabine shows significant cytotoxic effects against a variety of cultured murine and human<br />tumour cells. Its action is phase-specific such that gemcitabine primarily kills cells that are<br />undergoing DNA synthesis (S phase) and, under certain circumstances, blocks the progression of cells<br />at the junction of the G1/S phase boundary. In vitro, the cytotoxic effect of gemcitabine is<br />dependent on both concentration and time.<br />Antitumoral activity in preclinical models<br />In animal tumour models, antitumoural activity of gemcitabine is schedule-dependent. When<br />gemcitabine is administered daily, high mortality among the animals but minimal antitumoural<br />activity is observed. If, however, gemcitabine is given every third or fourth day, it can be<br />administered in non-lethal doses with substantial antitumoural activity against a broad spectrum of<br />mouse tumours.<br />Mechanism of action<br />Cellular metabolism and mechanism of action: Gemcitabine (dFdC), which is a pyrimidine<br />antimetabolite, is metabolised intracellularly by nucleoside kinase to the active diphosphate<br />(dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effect of gemcitabine is due to</p><p>inhibition of DNA synthesis by two mechanisms of action by dFdCDP and dFdCTP. First, dFdCDP<br />inhibits ribonucleotide reductase, which is uniquely responsible for catalysing the reactions that<br />produce deoxynucleoside triphosphates (dCTP) for DNA synthesis. Inhibition of this enzyme by<br />dFdCDP reduces the concentration of deoxynucleosides in general and, in particular, dCTP. Second,<br />dFdCTP competes with dCTP for incorporation into DNA (self-potentiation).<br />Likewise, a small amount of gemcitabine may also be incorporated into RNA. Thus, the reduced<br />intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA. DNA<br />polymerase epsilon lacks the ability to eliminate gemcitabine and to repair the growing DNA strands.<br />After gemcitabine is incorporated into DNA, one additional nucleotide is added to the growing DNA<br />strands. After this addition there is essentially a complete inhibition in further DNA synthesis<br />(masked chain termination). After incorporation into DNA, gemcitabine appears to induce the<br />programmed cell death process known as apoptosis.<br />Clinical data<br />Bladder cancer<br />A randomised phase III study of 405 patients with advanced or metastatic urothelial transitional cell<br />carcinoma showed no difference between the two treatment arms, gemcitabine/cisplatin versus<br />methotrexate/vinblastine/adriamycin/cisplatin (MVAC), in terms of median survival (12.8 and 14.8<br />months respectively, p=0.547), time to disease progression (7.4 and 7.6 months respectively,<br />p=0.842) and response rate (49.4% and 45.7% respectively, p=0.512). However, the combination of<br />gemcitabine and cisplatin had a better toxicity profile than MVAC.<br />Pancreatic cancer<br />In a randomised phase III study of 126 patients with advanced or metastatic pancreatic cancer,<br />gemcitabine showed a statistically significant higher clinical benefit response rate than 5-fluorouracil<br />(23.8% and 4.8% respectively, p=0.0022). Also, a statistically significant prolongation of the time to<br />progression from 0.9 to 2.3 months (log-rank p&lt;0.0002) and a statistically significant prolongation of<br />median survival from 4.4 to 5.7 months (log-rank p&lt;0.0024) was observed in patients treated with<br />gemcitabine compared to patients treated with 5-fluorouracil.<br />Non small cell lung cancer<br />In a randomised phase III study of 522 patients with inoperable, locally advanced or metastatic<br />NSCLC, gemcitabine in combination with cisplatin showed a statistically significant higher response<br />rate than cisplatin alone (31.0% and 12.0%, respectively, p&lt;0.0001). A statistically significant<br />prolongation of the time to progression, from 3.7 to 5.6 months (log-rank p&lt;0.0012) and a<br />statistically significant prolongation of median survival from 7.6 months to 9.1 months (log-rank<br />p&lt;0.004) was observed in patients treated with gemcitabine/cisplatin compared to patients treated<br />with cisplatin.</p><p>In another randomised phase III study of 135 patients with stage IIIB or IV NSCLC, a combination of<br />gemcitabine and cisplatin showed a statistically significant higher response rate than a combination<br />of cisplatin and etoposide (40.6% and 21.2%, respectively, p=0.025). A statistically significant<br />prolongation of the time to progression, from 4.3 to 6.9 months (p=0.014) was observed in patients<br />treated with gemcitabine/cisplatin compared to patients treated with etoposide/cisplatin.<br />In both studies it was found that tolerability was similar in the two treatment arms.<br />Ovarian carcinoma<br />In a randomised phase III study, 356 patients with advanced epithelial ovarian carcinoma who had<br />relapsed at least 6 months after completing platinum based therapy were randomised to therapy<br />with gemcitabine and carboplatin (GCb), or carboplatin (Cb). A statistically significant prolongation<br />of the time to progression of disease, from 5.8 to 8.6 months (log-rank p= 0.0038) was observed in<br />the patients treated with GCb compared to patients treated with Cb. Differences in response rate of<br />47.2% in the GCb arm versus 30.9% in the Cb arm (p=0.0016) and median survival 18 months (GCb)<br />versus 17.3 (Cb) (p=0.73) favoured the GCb arm.<br />Breast cancer</p><p>In a randomised phase III study of 529 patients with inoperable, locally recurrent or metastatic<br />breast cancer with relapse after adjuvant/neoadjuvant chemotherapy, gemcitabine in combination<br />with paclitaxel showed a statistically significant prolongation of time to documented disease<br />progression from 3.98 to 6.14 months (log-rank p=0.0002) in patients treated with<br />gemcitabine/paclitaxel compared to patients treated with paclitaxel. After 377 deaths, the overall<br />survival was 18.6 months versus 15.8 months (log rank p=0.0489, HR 0.82) in patients treated with<br />gemcitabine/paclitaxel compared to patients treated with paclitaxel and the overall response rate<br />was 41.4% and 26.2% respectively (p= 0.0002).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of gemcitabine have been examined in 353 patients in seven studies. The 121<br />women and 232 men ranged in age from 29 to 79 years. Of these patients, approximately 45% had<br />non small cell lung cancer and 35% were diagnosed with pancreatic cancer. The following<br />pharmacokinetic parameters were obtained for doses ranging from 500 to 2,592 mg/m2 that were<br />infused from 0.4 to 1.2 hours.<br />Peak plasma concentrations (obtained within 5 minutes of the end of the infusion) were 3.2 to 45.5<br />&mu;g/ml. Plasma concentrations of the parent compound following a dose of 1,000 mg/m2/30 minutes<br />are greater than 5 &mu;g/ml for approximately 30 minutes after the end of the infusion, and greater<br />than 0.4 &mu;g/ml for an additional hour.<br />Distribution<br />The volume of distribution of the central compartment was 12.4 l/m2 for women and 17.5 l/m2 for<br />men (inter individual variability was 91.9%). The volume of distribution of the peripheral<br />compartment was 47.4 l/ m2. The volume of the peripheral compartment was not sensitive to<br />gender.<br />The plasma protein binding was considered to be negligible.<br />Half life: This ranged from 42 to 94 minutes depending on age and gender. For the recommended<br />dosing schedule, gemcitabine elimination should be virtually complete within 5 to 11 hours of the<br />start of the infusion. Gemcitabine does not accumulate when administered once weekly.<br />Metabolism<br />Gemcitabine is rapidly metabolised by cytidine deaminase in the liver, kidney, blood and other<br />tissues. Intracellular metabolism of gemcitabine produces the gemcitabine mono, di and<br />triphosphates (dFdCMP, dFdCDP and dFdCTP) of which dFdCDP and dFdCTP are considered active.<br />These intracellular metabolites have not been detected in plasma or urine. The primary metabolite,<br />2&#39; deoxy 2&#39;, 2&#39; difluorouridine (dFdU), is not active and is found in plasma and urine.<br />Excretion<br />Systemic clearance ranged from 29.2 l/hr/m2 to 92.2 /hr/m2 depending on gender and age (inter<br />individual variability was 52.2%). Clearance for women is approximately 25% lower than the values<br />for men. Although rapid, clearance for both men and women appears to decrease with age. For the<br />recommended gemcitabine dose of 1000 mg/m2 given as a 30 minute infusion, lower clearance<br />values for women and men should not necessitate a decrease in the gemcitabine dose.<br />Urinary excretion: Less than 10% is excreted as unchanged drug.<br />Renal clearance was 2 to 7 l/hr/m2.<br />During the week following administration, 92 to 98% of the dose of gemcitabine administered is<br />recovered, 99% in the urine, mainly in the form of dFdU and 1% of the dose is excreted in faeces.</p><p>dFdCTP kinetics<br />This metabolite can be found in peripheral blood mononuclear cells and the information below refers<br />to these cells. Intracellular concentrations increase in proportion to gemcitabine doses of<br />35-350 mg/m2/30 minutes, which give steady state concentrations of 0.4-5 &mu;g/ml. At gemcitabine</p><p>plasma concentrations above 5 &mu;g/ml, dFdCTP levels do not increase, suggesting that the formation<br />is saturable in these cells.<br />Half life of terminal elimination: 0.7-12 hours.<br />dFdU kinetics<br />Peak plasma concentrations (3-15 minutes after end of 30 minute infusion, 1000 mg/m2):<br />28-52 &mu;g/ml. Trough concentration following once weekly dosing: 0.07-1.12 &mu;g/ml, with no<br />apparent accumulation. Triphasic plasma concentration versus time curve, mean half life of<br />terminal phase 65 hours (range 33-84 hr).<br />Formation of dFdU from parent compound: 91% -98%.<br />Mean volume of distribution of central compartment: 18 l/m2 (range 11-22 l/m2).<br />Mean steady state volume of distribution (Vss): 150 l/m2 (range 96-228 l/m2).<br />Tissue distribution: Extensive.<br />Mean apparent clearance: 2.5 l/hr/m2 (range 1-4 l/hr/m2).<br />Urinary excretion: All.<br />Gemcitabine and paclitaxel combination therapy<br />Combination therapy did not alter the pharmacokinetics of either gemcitabine or paclitaxel.<br />Gemcitabine and carboplatin combination therapy<br />When given in combination with carboplatin the pharmacokinetics of gemcitabine were not altered<br />Renal impairment<br />Mild to moderate renal insufficiency (GFR from 30 ml/min to 80 ml/min) has no consistent,<br />significant effect on gemcitabine pharmacokinetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeat dose studies of up to 6 months in duration in mice and dogs, the principal finding was<br />schedule and dose-dependent haematopoietic suppression which was reversible.<br />Gemcitabine is mutagenic in an in vitro mutation test and an in vivo bone marrow micronucleus test.<br />Long term animal studies evaluating the carcinogenic potential have not been performed.<br />In fertility studies, gemcitabine caused reversible hypospermatogenesis in male mice. No effect on<br />the fertility of females has been detected.<br />Evaluation of experimental animal studies has shown reproductive toxicity e.g. birth defects and<br />other effects on the development of the embryo or foetus, the course of gestation or peri- and<br />postnatal development</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol E421<br />Sodium acetate trihydrate<br />Sodium hydroxide 1 N (for pH adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in<br />section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder
2 years.
Reconstituted solution
Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C. From a
microbiological point of view, the product should be used immediately. If not used immediately, inuse
storage times and conditions prior to use are the responsibility of the user.
Solutions of reconstituted gemcitabine should not be refrigerated, as crystallisation may occur.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not refrigerate or freeze.<br />For storage conditions of the reconstituted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gemcitabine Actavis is packed in colourless glass vials (type I) with bromobutylic rubber stopper and<br />sealed with aluminium seals with polypropylene caps. The vial will be packed with or without a<br />protective plastic overwrap.<br />Pack sizes<br />One vial containing 200 mg gemcitabine.<br />One vial containing 1 g gemcitabine.<br />One vial containing 2 g gemcitabine.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Handling<br />The normal safety precautions for cytostatic agents must be observed when preparing and disposing<br />of the infusion solution. Handling of the solution for infusion should be done in a safety box and<br />protective coats and gloves should be used. If no safety box is available, the equipment should be<br />supplemented with a mask and protective glasses.<br />If the preparation comes into contact with the eyes, this may cause serious irritation. The eyes<br />should be rinsed immediately and thoroughly with water. If there is lasting irritation, a doctor should<br />be consulted. If the solution is spilled on the skin, rinse thoroughly with water.<br />Instructions for reconstitution (and further dilution, if performed)<br />The only approved diluent for reconstitution of gemcitabine sterile powder is sodium chloride<br />9 mg/ml (0.9%) solution for injection (without preservative). Due to solubility considerations, the<br />maximum concentration for gemcitabine upon reconstitution is 40 mg/ml. Reconstitution at<br />concentrations greater than 40 mg/ml may result in incomplete dissolution and should be avoided.<br />1. Use aseptic technique during the reconstitution and any further dilution of gemcitabine for<br />intravenous infusion administration.<br />2. To reconstitute, add the appropriate volume of sterile sodium chloride 9 mg/ml (0.9%) solution<br />for injection without preservative (as stated in the table below) and shake to dissolve:</p><p>Presentation Volume of sterile<br />sodium chloride 9<br />mg/ml (0.9%) solution<br />for injection (without<br />Total volume after<br />reconstitution<br />Final concentration</p><p>preservative) to be<br />added<br />200 mg 5 ml 5.26 ml 38 mg/ml<br />1 g 25 ml 26.3 ml 38 mg/ml<br />2 g 50 ml 52.6 ml 38 mg/ml<br />Further dilution with sterile sodium chloride 9 mg/ml (0.9 %) solution for injection, without<br />preservative can be done. Reconstituted solution is a clear colourless to light straw-coloured<br />solution.<br />3. Parenteral medicinal products should be inspected visually for particulate matter and<br />discolouration prior to administration. If particulate matter is observed, do not administer.<br />Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Actavis Group PTC ehf.
Reykjavikurvegur 76-78
220 Hafnarfjordur
Iceland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2011
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>